Abbott Vascular's Xience Sierra Stent Receives National Reimbursement in Japan
May 4, 2018—Abbott Vascular announced that Japan's Ministry of Health, Labor, and Welfare granted national reimbursement for the company's Xience Sierra everolimus-eluting coronary stent. The device was approved in Japan on April 4, 2018.
According to the company, national reimbursement in Japan will enable doctors to treat more patients with Xience Sierra through the country's health insurance plans. The device received CE Mark approval in Europe in 2017. In the United States, it is an investigational device under review with the US Food and Drug Administration.
Xience Sierra is the newest generation of Abbott Vascular's Xience devices for the interventional treatment of coronary artery disease. It features an enhanced stent design, new delivery system, and unique sizes to help physicians treat challenging cases. The device is designed to more easily treat patients with multiple blockages, totally occluded arteries, or comorbid factors such as diabetes, stated the company.